Kestra (KMTS) Director Conor Hanley Sells Shares, Receives RSUs

What Happened

• Conor Hanley, a director at Kestra Medical Technologies (KMTS), executed a nondiscretionary sale of 5,694 shares on 2026-09-08 for a weighted average price of $25.25, generating proceeds of $143,779. The filing also reports an award of 7,217 restricted stock units (RSUs) on 2026-09-09 (acquisition code A).
• The sale was a sell-to-cover transaction to satisfy tax withholding obligations related to RSU vesting/settlement, per the filing; the RSUs reported are subject to vesting conditions.

Key Details

• Transactions and prices:
  • 2026-09-08 — Sale (S): 5,694 shares @ weighted avg $25.25 (range $24.91–$25.51); proceeds $143,779.
  • 2026-09-09 — Award/Grant (A): 7,217 RSUs (no per-share price reported for awards).
• Shares owned after the transactions: Not disclosed in the provided filing.
• Footnotes of note:
  • F1: Sale was nondiscretionary sell-to-cover to satisfy tax withholding on RSU vesting/settlement.
  • F2: Price shown is a weighted average; sale prices ranged $24.91–$25.51.
  • F3: Each RSU converts to one common share; the RSUs will vest on September 9, 2027, subject to continued service.
• Filing timeliness: Report filed 2026-09-10 for transactions on 2026-09-08 and 2026-09-09 — appears timely (not reported late).

Context

• The sale was a routine sell-to-cover tied to tax withholding and does not, by itself, indicate a change in the director’s view of the company. The award is an RSU grant that vests in one year (9/9/2027) if service conditions are met; RSUs are a common form of long-term compensation rather than an immediate open-market purchase.